Scientists have developed an mRNA technology approach to target the toxic protein tau, which builds up in patients with Alzheimer’s disease and other dementias.
To date, mRNA has been predominantly used for vaccines, including those used to fight COVID-19.
New research published in Brain Communications.
“This is the first time mRNA has been explored for use in Alzheimer’s disease,” the author said. “Our work in cell models demonstrates that this technology can serve purposes other than vaccine development.”
The author likened mRNA to an instruction manual for cells.
“Once delivered to the cell, the cell reads the mRNA and makes an antibody.”
The team used mRNA to instruct cells in cell models to create RNJ1, an antibody developed to target tau, a protein that clumps in the brain cells of dementia patients.
“This is the first time, to our knowledge, a tau antibody has been able to directly engage tau within the cell.”
First author on the paper said: “Our technique can be applied to any therapeutic antibody, and we envision that this strategy, when combined with nanoparticle packaging, will enhance targeting of toxic molecules in the brain and improve patient outcomes compared to conventional strategies.”
The author said emerging Alzheimer’s treatments, such as lecanemab, which is approved in the USA and under consideration in Australia, are promising but expensive to make and are not an efficient way of getting an active antibody into brain cells.
“With conventional antibodies, such as lecanemab, the small amount of antibody that does enter the brain can remove some harmful plaque that lies outside our brain cells but can’t access toxic proteins such as tau, which is located in our brain cells,” the author said.
https://academic.oup.com/braincomms/advance-article/doi/10.1093/braincomms/fcae100/7634511
Latest News
Pan-cancer proteogenomics e…
By newseditor
Posted 05 Jul
Fertility treatments could…
By newseditor
Posted 05 Jul
Extended-release ketamine t…
By newseditor
Posted 05 Jul
How an unstructured protein…
By newseditor
Posted 04 Jul
Precise control of endogeno…
By newseditor
Posted 04 Jul
Other Top Stories
Ebola virus protein exploits human RNA to change shape
Read more
Opening the mechanosensitive bacterial channel
Read more
One dose of SARS-CoV-2 mRNA vaccine may induce immunity in recovere…
Read more
Epigenetic factors predicting the severity of COVID-19
Read more
Defects in goblet cells may cause ulcerative colitis
Read more
Protocols
Pan-cancer proteogenomics c…
By newseditor
Posted 05 Jul
A systems biology-based ide…
By newseditor
Posted 05 Jul
Tongue orthotopic xenograft…
By newseditor
Posted 04 Jul
Monitoring norepinephrine r…
By newseditor
Posted 01 Jul
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Publications
Prevention of Falls in Olde…
By newseditor
Posted 05 Jul
The primitive endoderm supp…
By newseditor
Posted 05 Jul
Migrasome biogenesis: when…
By newseditor
Posted 05 Jul
Extended-release ketamine t…
By newseditor
Posted 05 Jul
Regulation of stress-induce…
By newseditor
Posted 04 Jul
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar